Stocks:
5,169
ETFs:
2,288
Exchanges:
11
Market Cap:
$65.13T
24h Vol:
$10.98B
Dominance:
MSFT:4.85%
Stocklytics Platform
Asset logo  ABBV
AbbVie
ABBV
62 / 100
S&P500
$154.78arrow_drop_down0.35%-$0.55

Performance History

Chart placeholder
Key Stats
Open$154.89
Prev. Close$155.34
EPS3.36
Dividend$6.06
Next Earnings DateAug 13, 2024
Dividend Yield %3.95%
Market Cap$293.87B
PE Ratio46.07
LOWHIGH
Day Range153.67
156.38
52 Week Range130.96
182.89
Ratios
P/B Ratio27.74
Revenue$54.31B
Operating M. %28.29%
Earnings$4.88B
Earnings Growth %-58.78%
EBITDA Margin %48.08%
ROE %56.24%
EPS3.36

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$808.45
24H (%)arrow_drop_up0.69%
24H ($)$5.54
MARKET CAP$744.33B
PRICE$516.83
24H (%)arrow_drop_down0.86%
24H ($)-$4.51
MARKET CAP$476.05B
PRICE$149.70
24H (%)arrow_drop_down2.47%
24H ($)-$3.80
MARKET CAP$364.05B
PRICE$131.09
24H (%)0.00%
24H ($)-$0.01
MARKET CAP$332.27B

About AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Sector
Healthcare
Industry
Drug Manufacturers—General
CEO
Mr. Richard A. Gonzalez
Headquarters
North Chicago
Employees
50000
Exchange
NYSE
add AbbVie  to watchlist

Keep an eye on AbbVie

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is AbbVie 's (ABBV) price per share?

The current price per share for AbbVie (ABBV) is $158.26. The stock has seen a price change of -$1.35 recently, indicating a -0.85% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for AbbVie (ABBV)?

For AbbVie (ABBV), the 52-week high is $182.89, which is 15.56% from the current price. The 52-week low is $130.96, the current price is 20.85% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is AbbVie (ABBV) a growth stock?

AbbVie (ABBV) has shown an average price growth of 0.41% over the past three years. It has received a score of 78 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying AbbVie as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is AbbVie (ABBV) stock price performance year to date (YTD)?

As of the latest data, AbbVie (ABBV) has a year-to-date price change of -0.98%. Over the past month, the stock has experienced a price change of -2.02%. Over the last three months, the change has been -11.58%. Over the past six months, the figure is 13.78%. Looking at a longer horizon, the five-year price change stands at 102.82%.

help
Is AbbVie (ABBV) a profitable company?

AbbVie (ABBV) has a net income of $4.88B, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 83.84% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 28.29% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $54.32B, although specific revenue growth data is currently not available. The gross profit is $45.54B. Operating income is noted at $17.42B. Furthermore, the EBITDA is $19.41B.

help
What is the market capitalization of AbbVie (ABBV)?

AbbVie (ABBV) has a market capitalization of $293.88B. The average daily trading volume is 4.33M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level